Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
J01CR05	PIPERACILINA/TAZOBACTAM SALA	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	913,813 L.L
J01CR05	PIPERACILLIN/TAZOBACTAM PANPHARMA	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	7,461,939 L.L
J01CR05	PIPERACILLIN/TAZOBACTAM SANDOZ	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	913,813 L.L
J01CR05	PIPERACILLIN/TAZOBACTAM STRAGEN	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	897,687 L.L
J01CR05	PIPERACILLIN/TAZOBACTAM STRAGEN	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	7,820,986 L.L
J01CR05	PIPERACILLINE/ TAZOBACTAM ARROW	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 500mg		Injectable powder for solution	7,378,682 L.L
J01CR05	PIPTAZ-ORBUCELL	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	1,087,873 L.L
J01CR05	PRIZMA	G	Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g		Injectable powder for solution	913,813 L.L
J01EE01	PAEDIATRIC CO-TRIMOXAZOLE MIXTURE	G	Trimethoprim - 40mg/5ml, Sulfamethoxazole - 200mg/5ml		Suspension	190,698 L.L
J01MA12	PILOQ	G	Levofloxacin - 500mg/100ml	500mg/100ml	Injectable solution	980,365 L.L
J01XD02	PROTOGYN	G	Tinidazole - 500mg	500mg	Tablet, film coated	223,078 L.L
J02AC01	PANZIMOL	G	Fluconazole - 100mg	100mg	Capsule, hard	2,015,764 L.L
J02AC01	PANZIMOL	G	Fluconazole - 150mg	150mg	Capsule, hard	428,686 L.L
J05AG06	PIFELTRO	B	Doravirine - 100mg	100mg	Tablet, film coated	27,819,434 L.L
J05AX18	PREVYMIS	B	Letermovir - 240mg	240mg	Tablet, film coated	460,943,945 L.L
J05AX18	PREVYMIS	B	Letermovir - 480mg	480mg	Tablet, film coated	961,233,292 L.L
J05AX18	PREVYMIS	B	Letermovir - 240mg/12ml	240mg/12ml	Injectable concentrate for solution	23,599,640 L.L
J06BA02	PRIVIGEN	BioHuman	Immunoglobulin human - 5g/50ml	10%	Injectable solution	44,463,925 L.L
J07AL01	PNEUMOVAX 23	B	Polysaccharides from each of 23 capsular types of Streptococcus pneumoniae - 25mcgx23serotypes/0.5ml		Injectable solution	2,378,601 L.L
J07AL02	PREVENAR 13	B	Polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 23F (2.2mcg)Polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125mg aluminium) -		Injectable suspension	6,352,343 L.L
J07AL02	PNEUMOSIL (10-VALENT)	G	Pneumococcal polysaccharide conjugate vaccine (adsorbed) -		Injectable suspension	3,386,483 L.L
J07AL02	PREVENAR 20	B	Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F,8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F, 33F (2.2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein (approximately 51mcg) adsorbed on aluminium phosphate (0.125mg aluminium) -		Injectable suspension	7,415,107 L.L
J07BD52	PRIORIX	B	Rubella virus live attenuated - ?10³ CCID50, Mumps virus live attenuated - ?103.7 CCID50, Measles virus live attenuated - ?10³ CCID50		Injectable lyophilised powder for solution+diluent	1,142,266 L.L
J07BF03	POLIOMYELITIS VACCINE INACTIVATED	B	Poliomyelitis virus type 1 inactivated - 40D.U, Poliomyelitis virus type 2 inactivated - 8D.U, Poliomyelitis virus type 3 inactivated - 32D.U		Injectable suspension	1,206,771 L.L
J07CA06	PENTAXIM	B	Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg		Injectable dry powder+suspension	2,558,676 L.L
L01BA04	PEMETREXED ACCORD	G	Pemetrexed (disodium) - 500mg	500mg	Injectable powder for concentrate for solution	20,000,292 L.L
L01BA04	PEMETREXED EVER PHARMA	G	Pemetrexed (disodium) - 500mg/20ml	500mg/20ml	Injectable concentrate for solution	38,618,714 L.L
L01BA04	PEMETREXED GP PHARM	G	Pemetrexed (disodium) - 500mg	500mg	Injectable lyophilised powder	46,641,484 L.L
L01BA04	PEMETREXED NEAPOLIS	G	Pemetrexed (disodium) - 500mg		Injectable powder	41,289,202 L.L
L01BA04	PEMETREXED SPC	G	Pemetrexed (disodium) - 500mg	500mg	Injectable concentrated powder for solution	43,746,515 L.L

...